A randomized, placebo-controlled trial of alagebrium in patients with insulin-dependent type 1 diabetes and microalbuminuria
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2015
At a glance
- Drugs Alagebrium chloride (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Biomarker; Therapeutic Use
- Sponsors Synvista Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 02 Feb 2009 Status changed from recruiting to discontinued, according to clinicaltrials.gov; the reason stated was financial constraint.
- 21 Aug 2008 Status changed from not yet recruiting to recruiting.